Welcome to our dedicated page for Cara Therapeutic news (Ticker: CARA), a resource for investors and traders seeking the latest updates and insights on Cara Therapeutic stock.
Cara Therapeutics, Inc. (CARA) is a biopharmaceutical company whose public communications focus on pruritus, or chronic itch, and on the development and commercialization of difelikefalin-based therapies. News about Cara Therapeutics often centers on its clinical programs, commercial collaborations, and corporate actions that affect shareholders.
Company press releases describe the development of an IV formulation of difelikefalin, which is approved in the United States, European Union, and multiple other countries for moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis, with this IV formulation out-licensed worldwide. News items also discuss the company’s efforts to develop an oral formulation of difelikefalin for chronic pruritus associated with notalgia paresthetica, including details of the Phase 2/3 KOURAGE clinical program and the outcome of the KOURAGE-1 Part A study.
Investors following CARA-related news will see updates on clinical trial enrollment and readouts, such as announcements that oral difelikefalin did not demonstrate a meaningful clinical benefit compared to placebo in notalgia paresthetica and the resulting decision to discontinue that program. News releases also cover financial results, revenue from KORSUVA injection and related collaborations, and information about royalty and milestone arrangements.
Cara Therapeutics’ news flow additionally includes corporate and capital structure developments, such as reverse stock splits, plans to regain compliance with Nasdaq listing requirements, exploration of strategic alternatives, and a proposed merger with Tvardi Therapeutics, Inc. The company has announced a 1-for-12 reverse stock split and a later 1-for-3 reverse stock split in connection with the proposed merger, with expectations regarding a transition to a new company name and ticker symbol after the anticipated closing of that merger.
This news page allows readers to review these types of updates in one place, including clinical, commercial, financial, and corporate announcements related to Cara Therapeutics and the historical CARA ticker.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.